Trial Profile
A randomised, double-blind, phase III efficacy and safety study of cediranib (RECENTIN) when added to cisplatin plus a fluoropyrimidine, compared with cisplatin plus a fluoropyrimidine alone, in patients with previously untreated, locally advanced or metastatic, unresectable Gastric Cancer (GC)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 14 Jul 2017
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Cisplatin; Fluoropyrimidine derivatives
- Indications Gastric cancer
- Focus Therapeutic Use
- 01 Aug 2012 Planned end date (14 Oct 2014) added as reported by European Clinical Trials Database record.
- 14 Jun 2011 New trial record